颅脊髓照射中海马保护:海马旁转移发生率研究
该研究纳入51例高危髓母细胞瘤患者,基于三维磁共振按RTOG 0933图谱勾画海马,评估海马旁转移分布。中位随访2.4年,诊断时28例有脑转移、2例复发时出现脑转移;初诊无脑转移的18例(含M1)接受36 Gy后,海马旁区域均未出现继发病灶。结果提示无转移的高危髓母细胞瘤患者可考虑评估海马保护的全脑照射策略。
要点
- 初诊无脑转移的高危髓母细胞瘤患者接受36 Gy后,海马旁区域未出现继发病灶。
- 诊断时脑转移患者中海马旁转移比例:第一海马旁区16%,其余海马旁区43%。
- 未发现与海马旁转移发生显著相关的临床或生物学因素。
核心结论
- 结果提示,海马保护的全脑照射策略应在无转移的高危髓母细胞瘤亚组中进行评估。
研究设计与样本
- 2008至2011年纳入51例高危髓母细胞瘤患者,按法国PNET HR+5试验治疗,基于三维磁共振按RTOG 0933图谱手动勾画海马。
- 海马旁区域定义为距海马0至5 mm为第一海马旁区,5至15 mm为其余海马旁区。
主要发现
- 中位年龄8.79岁,女性占33%;随访2.4年后43例存活。
- 诊断时28例有脑转移,复发时2例出现脑转移;海马旁转移在第一海马旁区占16%,其余海马旁区占43%。
- 初诊无脑转移的18例(含M1)接受36 Gy后,第一及其余海马旁区均未出现继发病灶。
- 未发现与海马旁转移发生显著相关的临床或生物学因素。
临床怎么用
- 对无转移的高危髓母细胞瘤患者,可考虑评估海马保护的全脑照射以减轻神经认知损害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify the incidence of patients with perihippocampal metastases to assess the risk of brain relapse when sparing the hippocampal area. Medulloblastoma (MB) represents 20% of pediatric brain tumors. For high-risk MB patients, the 3- to 5-year event-free survival rate has recently improved from 50% to >76%. Many survivors, however, experience neurocognitive side effects. Several retrospective studies of patients receiving whole brain irradiation (WBI) have suggested a relationship between the radiation dose to the hippocampus and neurocognitive decline. The hippocampal avoidance-WBI (HA-WBI) approach could partially reduce neurocognitive impairment in children treated for high-risk MB. METHODS AND MATERIALS: From 2008 to 2011, 51 patients with high-risk MB were treated according to the French trial primitive neuroectodermal tumor HR+5. Hippocampal contouring was manually generated on 3-dimensional magnetic resonance images according to the Radiation Therapy Oncology Group 0933 atlas. The distribution of metastases was assessed relative to the hippocampus: 0 to 5 mm for the first perihippocampal area and 5 to 15 mm for the rest of the perihippocampal area. RESULTS: The median patient age was 8.79 years (33% female). After a follow-up of 2.4 years, 43 patients were alive; 28 had had brain metastasis at diagnosis and 2 at relapse, with 16% in the first perihippocampal area and 43% in the rest of the perihippocampal area. Of the 18 patients without brain metastases at diagnosis, including M1 patients, none developed secondary lesions within the first or the rest of the perihippocampal area, after receiving 36 Gy. No clinical or biological factor was significantly associated with the development of perihippocampal metastases. CONCLUSIONS: Our results suggest the HA-WBI strategy should be evaluated for the subgroup of high-risk MB patients without metastatic disease.
引用
- Padovani L, Chapon F, André N, et al. Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases? Int J Radiat Oncol Biol Phys. 2017. PMID: 29485078. doi:10.1016/j.ijrobp.2017.12.265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。